Skip to main content
. 2021 May 25;21:602. doi: 10.1186/s12885-021-08291-9

Fig. 1.

Fig. 1

Progression-free survival (a) and overall survival (a) in two groups. T + C, EGFR-TKI combined with chemotherapy; T, EGFR-TKI monotherapy; PFS, progression-free survival; OS, overall survival